Tuberculous meningitis in adults: A review of a decade of developments focusing on prognostic factors for outcome

Future Microbiology

Volumn 7, Issue 9, 2012, Pages 1101-1116

  Brancusi, Flavia ^a   Farrar, Jeremy ^b   Heemskerk, Dorothee ^b  

^a PRINCETON UNIVERSITY   (United States)

^b OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

Author keywords

adult; diagnosis; genetics; immunopathology; prognostic factor; review; treatment; tuberculosis; tuberculous meningitis

Indexed keywords

ADENOSINE DEAMINASE; DEXAMETHASONE; ETHAMBUTOL; ISONIAZID; LACTIC ACID; LENALIDOMIDE; LEVOFLOXACIN; LIPOARABINOMANNAN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; THALIDOMIDE;

ADULT; CEREBROSPINAL FLUID ANALYSIS; CRANIAL NEUROPATHY; DIAGNOSTIC IMAGING; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; EARLY DIAGNOSIS; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROCEPHALUS; HYPONATREMIA; INTRACRANIAL HYPERTENSION; INTRACRANIAL TUBERCULOMA; MACHINE; MIXED INFECTION; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEIZURE; STROKE; TUBERCULOUS MENINGITIS;

ADOLESCENT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HIV INFECTIONS; HUMANS; MALE; MYCOBACTERIUM TUBERCULOSIS; PROGNOSIS; TUBERCULOSIS, MENINGEAL;

EID: 84866081688     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.12.86     Document Type: Review

References (114)

1. WHO Global Tuberculosis Programme. Treatment of Tuberculosis: GUIDELINES for National Programmes. WHO Press, Switzerland, 108 (2010).
2. Chatterjee S. Brain tuberculomas, tubercular meningitis, and post-tubercular hydrocephalus in children. J. Pediatr. Neurosci. 6(Suppl. 1), S96-S100 (2011).
3. Thwaites GE, Tran TH. Tuberculous meningitis: Many questions, too few answers. Lancet Neurol. 4(3), 160-170 (2005).
4. Thwaites GE, Nguyen DB, Nguyen HD et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N. Engl. J. Med. 351(17), 1741-1751 (2004).
5. Torok ME, Yen NT, Chau TT et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis. Clin. Infect. Dis. 52(11), 1374-1383 (2011).
6. Hosoglu S, Geyik MF, Balik I et al. Predictors of outcome in patients with tuberculous meningitis. Int. J. Tuberc. Lung Dis. 6(1), 64-70 (2002).
7. Kalita J, Misra UK, Ranjan P. Predictors of long-term neurological sequelae of tuberculous meningitis: A multivariate analysis. Eur. J. Neurol. 14(1), 33-37 (2007).
8. Thwaites GE, Simmons CP, Than Ha Quyen N et al. Pathophysiology and prognosis in vietnamese adults with tuberculous meningitis. J. Infect. Dis. 188(8), 1105-1115 (2003).
9. Torok ME, Nguyen DB, Tran TH et al. Dexamethasone and long-term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One 6(12), e27821 (2011).
10. Medical Research Council. Streptomycin treatment of tuberculous meningitis. BMJ 582-597 (1948).
11. Donald PR, Schaaf HS, Schoeman JF. Tuberculous meningitis and miliary tuberculosis: The Rich focus revisited. J. Infect. 50(3), 193-195 (2005).
12. Rich AR, McCordock HA. The pathogenesis of tuberculous meningitis. Bull. John Hopkins Hosp. 52, 2-37 (1933).
13. Katti MK. Pathogenesis, diagnosis, treatment, and outcome aspects of cerebral tuberculosis. Med. Sci. Monit. 10(9), RA215-229 (2004).
14. Thwaites G, Chau TT, Mai NT, Drobniewski F, Mcadam K, Farrar J. Tuberculous meningitis. J. Neurol. Neurosurg. Psych. 68(3), 289-299 (2000).
15. North RJ, Jung YJ. Immunity to tuberculosis. Ann. Rev. Immunol. 22, 599-623 (2004).
16. Donald PR, Schoeman JF. Tuberculous meningitis. N. Engl. J. Med. 351(17), 1719-1720 (2004).
17. Lammie GA, Hewlett RH, Schoeman JF, Donald PR. Tuberculous cerebrovascular disease: A review. J. Infect. 59(3), 156-166 (2009).
18. Bernaerts A, Vanhoenacker FM, Parizel PM et al. Tuberculosis of the central nervous system: Overview of neuroradiological findings. Eur. Radiol. 13(8), 1876-1890 (2003).
19. Thwaites GE, Macmullen-Price J, Tran TH et al. Serial MRI to determine the effect of dexamethasone on the cerebral pathology of tuberculous meningitis: An observational study. Lancet Neurol. 6(3), 230-236 (2007).
20. Wasay M, Kheleani BA, Moolani MK et al. Brain CT and MRI findings in 100 consecutive patients with intracranial tuberculoma. J. Neuroimaging 13(3), 240-247 (2003).
21. Wasay M, Moolani MK, Zaheer J, Kheleani BA, Smego RA, Sarwari RA. Prognostic indicators in patients with intracranial tuberculoma: A review of 102 cases. J. Pak. Med. Assoc. 54(2), 83-87 (2004).
22. Roos KL. Mycobacterium tuberculosis meningitis and other etiologies of the aseptic meningitis syndrome. Semin. Neurol. 20(3), 329-335 (2000).
23. Anuradha HK, Garg RK, Sinha MK et al. Intracranial tuberculomas in patients with tuberculous meningitis: Predictors and prognostic significance. Int. J. Tuberc. Lung Dis. 15(2), 234-239 (2011).
24. Sharma P, Garg RK, Verma R, Singh MK, Shukla R. Incidence, predictors and prognostic value of cranial nerve involvement in patients with tuberculous meningitis: A retrospective evaluation. Eur. J. Intern. Med. 22(3), 289-295 (2011).
25. Villoria MF, Fortea F, Moreno S, Munoz L, Manero M, Benito C. MR imaging and CT of central nervous system tuberculosis in the patient with AIDS. Radiol. Clin. North Am. 33(4), 805-820 (1995).
26. Kalita J, Prasad S, Maurya PK, Kumar S, Misra UK. MR angiography in tuberculous meningitis. Acta Radiol. 53(3), 324-329 (2012).
27. Nair PP, Kalita J, Kumar S, Misra UK. MRI pattern of infarcts in basal ganglia region in patients with tuberculous meningitis. Neuroradiology 51(4), 221-225 (2009).
28. Shukla R, Abbas A, Kumar P, Gupta RK, Jha S, Prasad KN. Evaluation of cerebral infarction in tuberculous meningitis by diffusion weighted imaging. J. Infect. 57(4), 298-306 (2008).
29. Misra UK, Kalita J, Maurya PK. Stroke in tuberculous meningitis. J. Neurol. Sci. 303(1-2), 22-30 (2011).
30. Kalita J, Misra UK, Nair PP. Predictors of stroke and its significance in the outcome of tuberculous meningitis. J. Stroke Cerebrovasc. Dis. 18(4), 251-258 (2009).
31. Simmons CP, Thwaites GE, Quyen NT et al. Pretreatment intracerebral and peripheral blood immune responses in Vietnamese adults with tuberculous meningitis: Diagnostic value and relationship to disease severity and outcome. J. Immunol. 176(3), 2007-2014 (2006).
32. Green JA, Thi Hong Chau T, Farrar JJ, Friedland JS, Thwaites GE. CNS infection, CSF matrix metalloproteinase concentrations, and clinical/laboratory features. Neurology 76(6), 577-579 (2011).
33. Green JA, Tran CT, Farrar JJ et al. Dexamethasone, cerebrospinal fluid matrix metalloproteinase concentrations and clinical outcomes in tuberculous meningitis. PLoS One 4(9), e7277 (2009).
34. Cecchini D, Ambrosioni J, Brezzo C et al. Tuberculous meningitis in HIV-infected and non-infected patients: Comparison of cerebrospinal fluid findings. Int. J. Tuberc. Lung Dis. 13(2), 269-271 (2009).
35. Rock RB, Hu S, Gekker G et al. Mycobacterium tuberculosis-induced cytokine and chemokine expression by human microglia and astrocytes: Effects of dexamethasone. J. Infect. Dis. 192(12), 2054-2058 (2005).
36. Simmons CP, Thwaites GE, Quyen NT et al. The clinical benefit of adjunctive dexamethasone in tuberculous meningitis is not associated with measurable attenuation of peripheral or local immune responses. J. Immunol. 175(1), 579-590 (2005).
37. Tobin DM, Roca FJ, Oh SF et al. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 148(3), 434-446 (2012).
38. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: A meta-analysis and assessment of cost-effectiveness. Lancet 367(9517), 1173-1180 (2006).
39. Rodrigues LC, Mangtani P, Abubakar I. How does the level of BCG vaccine protection against tuberculosis fall over time? BMJ 343, d5974 (2011).
40. Sreevatsan S, Pan X, Stockbauer KE et al. Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination. Proc. Natl Acad. Sci. USA 94(18), 9869-9874 (1997).
41. Glynn JR, Alghamdi S, Mallard K et al. Changes in Mycobacterium tuberculosis genotype families over 20 years in a population-based study in northern Malawi. PLoS One 5(8), e12259 (2010).
42. Caws M, Thwaites G, Stepniewska K et al. Beijing genotype of Mycobacterium tuberculosis is significantly associated with human immunodeficiency virus infection and multidrug resistance in cases of tuberculous meningitis. J. Clin. Microbiol. 44(11), 3934-3939 (2006).
43. Thwaites G, Caws M, Chau TT et al. Relationship between Mycobacterium tuberculosis genotype and the clinical phenotype of pulmonary and meningeal tuberculosis. J. Clin. Microbiol. 46(4), 1363-1368 (2008).
44. Faksri K, Drobniewski F, Nikolayevskyy V et al. Epidemiological trends and clinical comparisons of Mycobacterium tuberculosis lineages in Thai TB meningitis. Tuberculosis (Edinb.) 91(6), 594-600 (2011).
45. Tho DQ, Torok ME, Yen NT et al. Influence of antituberculosis drug resistance and Mycobacterium tuberculosis lineage on outcome in HIV-associated tuberculous meningitis. Antimicrob. Agents Chemother. 56(6), 3074-3079 (2012).
46. Awomoyi AA, Marchant A, Howson JM, Mcadam KP, Blackwell JM, Newport MJ. Interleukin-10, polymorphism in SLC11A1 (formerly NRAMP1), and susceptibility to tuberculosis. J. Infect. Dis. 186(12), 1808-1814 (2002).
47. Bellamy R. Identifying genetic susceptibility factors for tuberculosis in Africans: A combined approach using a candidate gene study and a genome-wide screen. Clin. Sci. (Lond.) 98(3), 245-250 (2000).
48. Bellamy R. Susceptibility to mycobacterial infections: The importance of host genetics. Genes Immun. 4(1), 4-11 (2003).
49. Spira A, Carroll JD, Liu G et al. Apoptosis genes in human alveolar macrophages infected with virulent or attenuated Mycobacterium tuberculosis: A pivotal role for tumor necrosis factor. Am. J. Respir. Cell Mol. Biol. 29(5), 545-551 (2003).
50. Kleinnijenhuis J, Oosting M, Joosten LA, Netea MG, Van Crevel R. Innate immune recognition of Mycobacterium tuberculosis. Clin. Develop. Immunol. 2011, 405310 (2011).
51. Thuong NT, Dunstan SJ, Chau TT et al. Identification of tuberculosis susceptibility genes with human macrophage gene expression profiles. PLoS Pathog. 4(12), e1000229 (2008).
52. Hawn TR, Dunstan SJ, Thwaites GE et al. A polymorphism in Toll-interleukin 1 receptor domain containing adaptor protein is associated with susceptibility to meningeal tuberculosis. J. Infect. Dis. 194(8), 1127-1134 (2006).
53. Thwaites GE, Chau TT, Farrar JJ. Improving the bacteriological diagnosis of tuberculous meningitis. J. Clin. Microbiol. 42(1), 378-379 (2004).
54. Kumar P, Srivatsava MV, Singh S, Prasad HK. Filtration of cerebrospinal fluid improves isolation of mycobacteria. J. Clin. Microbiol. 46(8), 2824-2825 (2008).
55. Caws M, Dang TM, Torok E et al. Evaluation of the MODS culture technique for the diagnosis of tuberculous meningitis. PLoS One 2(11), e1173 (2007).
56. Ha DT, Lan NT, Wolbers M et al. Microscopic observation drug susceptibility assay (MODS) for early diagnosis of tuberculosis in children. PLoS One 4(12), e8341 (2009).
57. Hanif SN, Eldeen HS, Ahmad S, Mokaddas E. GeneXpert(R) MTB/RIF for rapid detection of Mycobacterium tuberculosis in pulmonary and extra-pulmonary samples. Int. J. Tuberc. Lung Dis. 15(9), 1274-1275 (2011).
58. Heemskerk D, Day J, Chau TT et al. Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): Protocol for a randomized controlled trial. Trials 12, 25 (2011).
59. Marais S, Thwaites G, Schoeman JF et al. Tuberculous meningitis: A uniform case definition for use in clinical research. Lancet Infect. Dis. 10(11), 803-812 (2010).
60. Brady T. Adenosine deaminase. Biochem. J. 36(5-6), 478-484 (1942).
61. Ocana I, Martinez-Vazquez JM, Segura RM, Fernandez-De-Sevilla T, Capdevila JA. Adenosine deaminase in pleural fluids. Test for diagnosis of tuberculous pleural effusion. Chest 84(1), 51-53 (1983).
62. Xu HB, Jiang RH, Li L, Sha W, Xiao HP. Diagnostic value of adenosine deaminase in cerebrospinal fluid for tuberculous meningitis: A meta-analysis. Int. J. Tuberc. Lung Dis. 14(11), 1382-1387 (2010).
63. Garcia-Monco C, Berciano J. Sarcoid meningitis, high adenosine deaminase levels in CSF and results of cranial irradiation. J. Neurol. Neurosurg. Psych. 51(12), 1594-1596 (1988).
64. Lopez-Cortes LF, Cruz-Ruiz M, Gomez-Mateos J et al. Adenosine deaminase activity in the CSF of patients with aseptic meningitis: Utility in the diagnosis of tuberculous meningitis or neurobrucellosis. Clin. Infect. Dis. 20(3), 525-530 (1995).
65. Chan J, Fan XD, Hunter SW, Brennan PJ, Bloom BR. Lipoarabinomannan, a possible virulence factor involved in persistence of Mycobacterium tuberculosis within macrophages. Infect. Immun. 59(5), 1755-1761 (1991).
66. Patel VB, Singh R, Connolly C et al. Comparison of a clinical prediction rule and a LAM antigen-detection assay for the rapid diagnosis of TBM in a high HIV prevalence setting. PLoS One 5(12), e15664 (2010).
67. Pai M, Flores LL, Pai N, Hubbard A, Riley LW, Colford JM Jr. Diagnostic accuracy of nucleic acid amplification tests for tuberculous meningitis: A systematic review and meta-analysis. Lancet Infect. Dis. 3(10), 633-643 (2003).
68. Pai M, Ling DI. Rapid diagnosis of extrapulmonary tuberculosis using nucleic acid amplification tests: What is the evidence? Future Microbiol. 3(1), 1-4 (2008).
69. Evans CA. GeneXpert - a game-changer for tuberculosis control? PLoS Med. 8(7), e1001064 (2011).
70. Boehme CC, Nicol MP, Nabeta P et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: A multicentre implementation study. Lancet 377(9776), 1495-1505 (2011).
71. Hillemann D, Rusch-Gerdes S, Boehme C, Richter E. Rapid molecular detection of extrapulmonary tuberculosis by the automated GeneXpert MTB/RIF system. J. Clin. Microbiol. 49(4), 1202-1205 (2011).
72. Thwaites GE, Lan NT, Dung NH et al. Effect of antituberculosis drug resistance on response to treatment and outcome in adults with tuberculous meningitis. J. Infect. Dis. 192(1), 79-88 (2005).
73. Thwaites G, Fisher M, Hemingway C, Scott G, Solomon T, Innes J. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J. Infect. 59(3), 167-187 (2009).
74. American Thoracic Society; CDC; Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm. Rep. 52(RR-11), 1-77 (2003).
75. McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob. Agents Chemother. 50(4), 1170-1177 (2006).
76. Tappero JW, Bradford WZ, Agerton TB et al. Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin. Infect. Dis. 41(4), 461-469 (2005).
77. Wilkins JJ, Langdon G, McIlleron H, Pillai GC, Smith PJ, Simonsson US. Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients. Eur. J. Clin. Pharmacol. 62(9), 727-735 (2006).
78. Ellard GA, Humphries MJ, Gabriel M, Teoh R. Penetration of pyrazinamide into the cerebrospinal fluid in tuberculous meningitis. Br. Med. J. (Clin. Res. Ed.) 294(6567), 284-285 (1987).
79. Barling RW, Selkon JB. The penetration of antibiotics into cerebrospinal fluid and brain tissue. J. Antimicrob. Chemother. 4(3), 203-227 (1978).
80. Krishnan N, Malaga W, Constant P et al. Mycobacterium tuberculosis lineage influences innate immune response and virulence and is associated with distinct cell envelope lipid profiles. PLoS One 6(9), e23870 (2011).
81. Gumbo T, Louie A, Deziel MR et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob. Agents Chemother. 51(11), 3781-3788 (2007).
82. Ruslami R, Nijland H, Aarnoutse R et al. Evaluation of high- versus standard-dose rifampin in Indonesian patients with pulmonary tuberculosis. Antimicrob. Agents Chemother. 50(2), 822-823 (2006).
83. Ruslami R, Nijland HM, Alisjahbana B, Parwati I, Van Crevel R, Aarnoutse RE. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob. Agents Chemother. 51(7), 2546-2551 (2007).
84. Thwaites GE, Bhavnani SM, Chau TT et al. Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis. Antimicrob. Agents Chemother. 55(7), 3244-3253 (2011).
85. Peloquin CA, Hadad DJ, Molino LP et al. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob. Agents Chemother. 52(3), 852-857 (2008).
86. Martinez-Vazquez C, Bordon J, Rodriguez-Gonzalez A et al. Cerebral tuberculoma -a comparative study in patients with and without HIV infection. Infection 23(3), 149-153 (1995).
87. Udani PM, Parekh UC, Dastur DK. Neurological and related syndromes in CNS tuberculosis. Clinical features and pathogenesis. J. Neurol. Sci. 14(3), 341-357 (1971).
88. Murthy JM. Tuberculous meningitis: The challenges. Neurol. India 58(5), 716-722 (2010).
89. Duong DA, Nguyen TH, Nguyen TN et al. Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam. Antimicrob. Agents Chemother. 53(11), 4835-4839 (2009).
90. Patel VB, Padayatchi N, Bhigjee AI et al. Multidrug-resistant tuberculous meningitis in KwaZulu-Natal, South Africa. Clin Infect Dis 38(6), 851-856 (2004).
91. Vinnard C, Winston CA, Wileyto EP, Macgregor RR, Bisson GP. Isoniazid resistance and death in patients with tuberculous meningitis: Retrospective cohort study. BMJ 341, c4451 (2010).
92. Tsenova L, Bergtold A, Freedman VH, Young RA, Kaplan G. Tumor necrosis factor alpha is a determinant of pathogenesis and disease progression in mycobacterial infection in the central nervous system. Proc. Natl Acad. Sci. USA 96(10), 5657-5662 (1999).
93. Tsenova L, Mangaliso B, Muller G et al. Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis. Antimicrob. Agents Chemother. 46(6), 1887-1895 (2002).
94. Schoeman JF, Springer P, Van Rensburg AJ et al. Adjunctive thalidomide therapy for childhood tuberculous meningitis: Results of a randomized study. J. Child Neurol. 19(4), 250-257 (2004).
95. Prasad K, Singh MB. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst. Rev. (1), CD002244 (2008).
96. Thwaites GE, Duc Bang N, Huy Dung N et al. The influence of HIV infection on clinical presentation, response to treatment, and outcome in adults with tuberculous meningitis. J. Infect. Dis. 192(12), 2134-2141 (2005).
97. Torok ME, Chau TT, Mai PP et al. Clinical and microbiological features of HIVassociated tuberculous meningitis in Vietnamese adults. PLoS One 3(3), e1772 (2008).
98. Meintjes G, Lawn SD, Scano F et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: Case definitions for use in resource-limited settings. Lancet Infect. Dis. 8(8), 516-523 (2008).
99. Abdool Karim SS, Naidoo K, Grobler A et al. Integration of antiretroviral therapy with tuberculosis treatment. N. Engl. J. Med. 365(16), 1492-1501 (2011).
100. Blanc FX, Sok T, Laureillard D et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N. Engl. J. Med. 365(16), 1471-1481 (2011).
101. Torok ME, Farrar JJ. When to start antiretroviral therapy in HIV-associated tuberculosis. N. Engl. J. Med. 365(16), 1538-1540 (2011).
102. Schoeman J, Mansvelt E, Springer P, Van Rensburg AJ, Carlini S, Fourie E. Coagulant and fibrinolytic status in tuberculous meningitis. Pediatr. Infect. Dis. J. 26(5), 428-431 (2007).
103. Schoeman JF, Janse Van Rensburg A, Laubscher JA, Springer P. The role of aspirin in childhood tuberculous meningitis. J. Child Neurol. 26(8), 956-962 (2011).
104. Misra UK, Kalita J, Nair PP. Role of aspirin in tuberculous meningitis: A randomized open label placebo controlled trial. J. Neurol. Sci. 293(1-2), 12-17 (2010).
105. Figaji AA, Sandler SI, Fieggen AG, Le Roux PD, Peter JC, Argent AC. Continuous monitoring and intervention for cerebral ischemia in tuberculous meningitis. Pediatr. Crit. Care Med. 9(4), e25-30 (2008).
106. Ranjan P, Kalita J, Misra UK. Serial study of clinical and CT changes in tuberculous meningitis. Neuroradiology 45(5), 277-282 (2003).
107. Schoeman J, Donald P, Van Zyl L, Keet M, Wait J. Tuberculous hydrocephalus: Comparison of different treatments with regard to ICP, ventricular size and clinical outcome. Develop. Med. Child Neurol. 33(5), 396-405 (1991).
108. Figaji AA, Fieggen AG. The neurosurgical and acute care management of tuberculous meningitis: Evidence and current practice. Tuberculosis (Edinb.) 90(6), 393-400 (2010).
109. Rajshekhar V. Management of hydrocephalus in patients with tuberculous meningitis. Neurol. India 57(4), 368-374 (2009).
110. Murthy JM. Management of intracranial pressure in tuberculous meningitis. Neurocrit. Care 2(3), 306-312 (2005).
111. Smith R. Eradication of tuberculosis by 2050 impossible without new vaccine. BMJ 338,b1291 (2009).
112. Kaufmann SH. Fact and fiction in tuberculosis vaccine research: 10 years later.Lancet Infect. Dis. 11(8), 633-640 (2011).
113. Ma Z, Lienhardt C, Mcilleron H, Nunn AJ, Wang X. Global tuberculosis drug development pipeline: The need and the reality. Lancet 375(9731), 2100-2109 (2010).
114. Lienhardt C, Vernon A, Raviglione MC. New drugs and new regimens for the treatment of tuberculosis: Review of the drug development pipeline and implications for national programmes. Curr. Opin. Pulm. Med. 16(3), 186-193 (2010).